Skip to content

Maggie Kiraga

5 papers in the library · 162 citations · publishing 2021-2022

Papers

Sort Most recent Most cited

Author Correction: Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls.

Sci Rep July 28, 2022 Joseph M. Rootman, Maggie Kiraga, Pamela Kryskow et al. 2 citations

Author Correction: Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls.

Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees

Frontiers in Psychiatry July 7, 2022 Maggie Kiraga, Kim P. C. Kuypers, Malin V. Uthaug et al. 24 citations

Anxiety disorders are the most common type of psychiatric disorders among Western countries. Evidence-based treatment modalities including pharmacological and cognitive-behavioral therapy result in deficient treatment responses. Historical and recent research suggests psychedelic drugs may be efficacious in alleviating anxiety-related symptoms among healthy and clinical populations. The main...

Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls

Scientific Reports June 30, 2022 Joseph M. Rootman, Maggie Kiraga, Pamela Kryskow et al. 53 citations

Abstract Psilocybin microdosing involves repeated self-administration of mushrooms containing psilocybin at doses small enough to not impact regular functioning. Microdose practices are diverse and include combining psilocybin with substances such as lion’s mane mushrooms (Hericium erinaceus; HE) and niacin (vitamin-B3). Public uptake of microdosing has outpaced evidence, mandating further...

Persisting decreases in state and trait anxiety post-psilocybin: A naturalistic, observational study among retreat attendees

medRxiv March 2, 2022 Maggie Kiraga, Kim P. C. Kuypers, Malin V. Uthaug et al. preprint

Abstract Anxiety disorders are the most common type of psychiatric disorders among Western countries. Evidence-based treatment modalities including pharmacological and cognitive-behavioral therapy result in relatively low response rates (average range: 51 - 58%). Historical and recent research suggests psychedelic drugs may be efficacious in alleviating anxiety-related symptoms among healthy...

Persisting Effects of Ayahuasca on Empathy, Creative Thinking, Decentering, Personality, and Well-Being

Frontiers in Pharmacology October 1, 2021 Maggie Kiraga, Natasha L. Mason, Malin V. Uthaug et al. 83 citations

Background: Naturalistic and placebo-controlled studies have suggested that ayahuasca, a traditional Amazonian beverage, could be helpful in the treatment of psychopathologies like depression and anxiety disorders by changing otherwise disturbed cognitive and emotional processes. To better understand its full therapeutic potential, one way is to study the effects on processes like flexible...